Glucagon for Obesity
(GIO Trial)

Recruiting in Palo Alto (17 mi)

Overseen BySteven R Smith, MD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Translational Research Institute for Metabolism and Diabetes, Florida

No Placebo Group

Approved in 4 jurisdictions

Trial Summary

What is the purpose of this trial?To further understand the tolerability of glucagon.

Eligibility Criteria

Adults aged 18-55 with a BMI between 27 and 40, non-diabetic, in good health without significant medical conditions. Participants must not have had weight fluctuations or surgery recently, avoid alcohol, caffeine, strenuous activity before visits, and if female and able to bear children, use birth control.

Inclusion Criteria

Subject is willing to avoid strenuous physical activity for 72 hours prior to the inpatient study visit

I am using or willing to use birth control during the study.

Stable body weight for 3 months (self-reported loss/gain <5%)

+6 more

Exclusion Criteria

I have a serious heart condition.

I have anemia.

I have a metabolic, endocrine, or other similar disorder.

+16 more

Participant Groups

The trial is testing the tolerability of glucagon infusions in obese individuals. It aims to understand how well these participants can tolerate this hormone treatment which could potentially influence body weight regulation.

1Treatment groups

Experimental Treatment

Group I: Glucagon InfusionExperimental Treatment1 Intervention

Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.

Glucagon is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺 Approved in European Union as GlucaGen for: